Insufficient scRNA-seq data for expression of CCNF at single-cell level.
Insufficient scRNA-seq data for expression of CCNF at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 100% | 972.33 | 1809 / 1809 | 99% | 13.83 | 467 / 472 |
breast | 98% | 308.21 | 451 / 459 | 99% | 15.40 | 1105 / 1118 |
uterus | 97% | 183.76 | 165 / 170 | 99% | 18.96 | 455 / 459 |
bladder | 95% | 381.00 | 20 / 21 | 99% | 14.95 | 497 / 504 |
ovary | 97% | 200.58 | 175 / 180 | 94% | 10.01 | 403 / 430 |
lung | 97% | 258.08 | 558 / 578 | 94% | 10.91 | 1082 / 1155 |
intestine | 93% | 272.85 | 896 / 966 | 96% | 14.54 | 506 / 527 |
esophagus | 87% | 379.32 | 1251 / 1445 | 99% | 15.44 | 182 / 183 |
stomach | 83% | 216.96 | 298 / 359 | 96% | 13.95 | 274 / 286 |
prostate | 98% | 422.21 | 239 / 245 | 74% | 3.66 | 370 / 502 |
brain | 94% | 444.12 | 2479 / 2642 | 76% | 5.00 | 536 / 705 |
pancreas | 73% | 106.53 | 241 / 328 | 73% | 4.95 | 130 / 178 |
adrenal gland | 95% | 198.12 | 244 / 258 | 47% | 2.43 | 107 / 230 |
thymus | 98% | 212.28 | 643 / 653 | 22% | 4.07 | 136 / 605 |
liver | 70% | 114.31 | 158 / 226 | 46% | 2.93 | 186 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 22.81 | 29 / 29 |
spleen | 100% | 555.99 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 27.58 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.33 | 1 / 1 |
adipose | 94% | 190.79 | 1137 / 1204 | 0% | 0 | 0 / 0 |
kidney | 79% | 152.87 | 70 / 89 | 16% | 0.83 | 141 / 901 |
muscle | 89% | 172.56 | 715 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 83% | 4.37 | 66 / 80 |
peripheral blood | 77% | 886.92 | 718 / 929 | 0% | 0 | 0 / 0 |
heart | 52% | 67.89 | 449 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 39% | 53.35 | 520 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
GO_0051301 | Biological process | cell division |
GO_0001890 | Biological process | placenta development |
GO_0010826 | Biological process | negative regulation of centrosome duplication |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0000320 | Biological process | re-entry into mitotic cell cycle |
GO_0044772 | Biological process | mitotic cell cycle phase transition |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005813 | Cellular component | centrosome |
GO_0005814 | Cellular component | centriole |
GO_0000307 | Cellular component | cyclin-dependent protein kinase holoenzyme complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0030054 | Cellular component | cell junction |
GO_0005634 | Cellular component | nucleus |
GO_0016538 | Molecular function | cyclin-dependent protein serine/threonine kinase regulator activity |
GO_0005515 | Molecular function | protein binding |
GO_0010997 | Molecular function | anaphase-promoting complex binding |
Gene name | CCNF |
Protein name | Cyclin-F (F-box only protein 1) Cyclin F |
Synonyms | FBX1 FBXO1 |
Description | FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins . The SCF(CCNF) E3 ubiquitin-protein ligase complex is an integral component of the ubiquitin proteasome system (UPS) and links proteasome degradation to the cell cycle . Mediates the substrate recognition and the proteasomal degradation of various target proteins involved in the regulation of cell cycle progression and in the maintenance of genome stability . Mediates the ubiquitination and proteasomal degradation of CP110 during G2 phase, thereby acting as an inhibitor of centrosome reduplication . In G2, mediates the ubiquitination and subsequent degradation of ribonucleotide reductase RRM2, thereby maintaining a balanced pool of dNTPs and genome integrity . In G2, mediates the ubiquitination and proteasomal degradation of CDC6, thereby suppressing DNA re-replication and preventing genome instability . Involved in the ubiquitination and degradation of the substrate adapter CDH1 of the anaphase-promoting complex (APC/C), thereby acting as an antagonist of APC/C in regulating G1 progression and S phase entry . May play a role in the G2 cell cycle checkpoint control after DNA damage, possibly by promoting the ubiquitination of MYBL2/BMYB . . |
Accessions | H0Y2P7 P41002 H3BUD3 ENST00000293968.11 ENST00000397066.9 ENST00000564236.1 |